Under the Radar Biotechs To Research Now

May 30, 2019 -- InvestorsHub NewsWire -- via microcapspeculators.com -- While Amgen (AMGN) offering to buy a drug discovery platform biotech company, and the FDA approved the label expansion of lead drugs of Celgene (CELG) and Incyte (INCY), took most of the headlines, several under the radar biotech stocks have started to gain investor attention.

One company getting closer to a human trial, Propanc Biopharma, Inc. (USOTC: PPCB), initiated development of a bio-analytical assay in March ’19, intended to quantify the active ingredients of the company's lead product candidate, PRP, in preparation for human trials. This is just one step closer for a company that has been making steady progress over the past year or so.

The companies we’re highlighting today include: Propanc Biopharma, Inc. (USOTC: PPCB), Obalon Therapeutics, Inc. (NASDAQ: OBLN), Nobilis Health Corp. (HLTH), Biocept, Inc. (NASDAQ: BIOC), and Sesen Bio, Inc. (NASDAQ: SESN).

Propanc Biopharma, Inc. (USOTC: PPCB) (Market Cap: $3.033M; Share Price: $0.00895), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, was granted FDA Orphan Drug Designation status for its PRP treatment of pancreatic cancer almost a year back. This qualifies the company for seven-year FDA-administered market Orphan Drug Exclusivity (ODE), tax credits of up to 50% of R&D costs, potential for R&D grants, waived FDA fees, protocol assistance and possible clinical trial tax incentives if conducted in the U.S. The company is also close to first-in-human studies.

PPCB announced that the company has appointed Dr. Ralf Brandt to its Scientific Advisory Board (SAB). He will provide significant translational research expertise and clinical support advisory support services to the company's drug development pipeline.

PPCB is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from pancreatic, ovarian and colorectal cancers.

PPCB has a growing patent portfolio that larger healthcare companies could be very interested in. It is among many biotech’s that could be considered a bit oversold due to current market conditions.

________

Obalon Therapeutics, Inc. (NASDAQ: OBLN) (Market Cap: $38.938M; Share Price: $1.66) announced that it has entered into definitive agreements with investors for the purchase and sale of 5 million shares of common stock valued at $3 million. The firm said it has entered into definitive agreements with investors for the purchase and sale of five million shares of common stock, par value .001 cents per share, at an offering price of 60 cents per share, pursuant to a registered direct offering.

Obalon Therapeutics said it offers the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity.

________

Nobilis Health Corp. (HLTH) (Market Cap: $13.303M; Share Price: $0.1700) announced recently it has submitted a formal request with the NYSE to extend the company's deadline for filing its Q3 2018 financials. On November 15, 2018, Nobilis Health Corp. filed a current report on Form 8-K reporting that it had received a notice from the New York Stock Exchange that the company is not in compliance with the NYSE's continued listing requirements under the timely filing criteria established in Section 1007 of the NYSE American Company Guide, as a result of its failure to timely file its Quarterly Report on Form 10-Q for the three months ended September 30, 2018.

________

Biocept, Inc. (NASDAQ: BIOC) (Market Cap: $23.018M; Share Price: $1.22), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it has been awarded Chinese Patent No. ZL201080019566.9 entitled, DEVICES AND METHODS OF CELL CAPTURE AND ANALYSIS. The issued patent covers methods and devices for the capture of rare cells of interest, including CTCs that are shed into the blood stream by solid tumors where an antibody, or mixture of antibodies, and a microchannel are used for cell capture, detection, and analysis. The patent encompasses the use of any biological sample type of interest and is the 33rd patent issued to Biocept that is core to its liquid biopsy technology and commercial testing platforms.

________

Sesen Bio, Inc. (NASDAQ: SESN) (Market Cap: $196.288M; Share Price: $2.5339), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, announced that the company has completed its Type C CMC meeting and has reached agreement with the U.S. Food and Drug Administration (FDA) on the Analytical Comparability Plan, and that, subject to final comparability data to be provided in the BLA submission, no additional clinical trials to establish comparability are deemed necessary at this time.

Legal Disclaimer:

This article was written by Regal Consulting, LLC (“Regal Consulting”). Regal Consulting expects to be paid $3,000 for the article directly from PPCB. All payments were made directly by Propanc Biopharma, Inc. (PPCB) to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspeculators.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. PPCB was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.

http://www.regalconsultingllc.com/full legal disclaimer/

Full Legal Disclaimer Click Here.

Contact Information:

Company Name: ACR Communication LLC.

Contact Person: Media Manager

Email: info@microcapspeculators.com

Phone: 1-702-720-6310

Country: United States

SOURCE: microcapspeculators.com

Propanc Biopharma (PK) (USOTC:PPCB)
過去株価チャート
から 10 2024 まで 11 2024